MK-2206 free base is an allosteric Akt inhibitor that is both potent and selective, administered orally, exhibiting IC50 values of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. It demonstrates sensitivity in various breast cancer cell lines, including those with PIK3CA mutations and those exhibiting PTEN loss, indicating its potential for anticancer activities [1] [2].

Akt1:8 nM, Akt2:12 nM, Akt3:65 nM